logo
  

Myovant & Pfizer: Long-term Study Supports Potential Benefit Of Relugolix Combination Therapy

Myovant Sciences (MYOV) and Pfizer Inc. (PFE) reported positive data from the phase 3 LIBERTY randomized withdrawal study of relugolix combination therapy in women with uterine fibroids. The data showed the potential value of continued treatment for women with uterine fibroids, with those receiving relugolix combination therapy in the study experiencing meaningful symptom relief for up to two years.

The study met its primary endpoint with 78.4% of women who continued on relugolix combination therapy achieving the sustained responder rate through week 76 compared with 15.1% of women who discontinued treatment and initiated placebo at week 52. All three key secondary endpoints in the study were also achieved.

Relugolix combination tablet is under review by the FDA for the treatment of women with uterine fibroids, with a decision anticipated by June 1, 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
After Disney World, retail giant Walmart Inc. (WMT) makes it mandatory for all its employees to wear mask on their facilities in the "high-risk" states where the Delta variant of Coronavirus has become menacing. The orders will be in effect immediately. The Center for Disease Control and Prevention... Generac Power Systems is recalling 325,735 units of Generac and DR 6500 Watt and 8000 Watt portable generators for potential risk of finger amputation and crushing hazards, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. These include 4,575 units sold in Canada. Omaha, Nebraska- based Greater Omaha Packing is recalling around 295,236 pounds of raw beef products citing the possible presence of E. coli O157:H7, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The raw beef products intended for non-intact use were produced on July 13.
Follow RTT